Amgen’s Enbrel in Kids “Concerning” Say FDA Staff

June 16, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

WASHINGTON (Reuters) - Post-marketing reports of life-threatening complications in children given Amgen Inc's drug Enbrel for psoriasis are 'concerning,' U.S. Food and Drug Administration staff said in documents released on Monday.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Postmarket research

Amgen Food and Drug Administration (FDA)